GISELA MD SCHWAB Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for GISELA MD SCHWAB.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of GISELA MD SCHWAB. GISELA MD SCHWAB is Chief Medical Officer in ABGENIX INC ($ABGX) and EVP and Chief Medical Officer in EXELIXIS, INC. ($EXEL) and Pres Prod Dev & Med Aff & CMO in EXELIXIS, INC. ($EXEL) and Pres, Prod Dev & Med Aff & CMO in EXELIXIS, INC. ($EXEL) and Director in GENOCEA BIOSCIENCES, INC. ($GNCA).
Latest Insider Trading Transactions of GISELA MD SCHWAB
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ABGX, EXEL, GNCA
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 14 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 1.90 | 100,000 | 190,000 | 150,000 | |
May 14 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 25.38 | 100,000 | 2,538,000 | 614,078 | 714.1 K to 614.1 K (-14.00 %) |
May 14 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 1.90 | 100,000 | 190,000 | 714,078 | 614.1 K to 714.1 K (+16.28 %) |
Apr 28 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 1.70 | 50,000 | 85,000 | 0 | |
Apr 28 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 25.00 | 50,000 | 1,250,000 | 613,482 | 663.5 K to 613.5 K (-7.54 %) |
Apr 28 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 1.70 | 50,000 | 85,000 | 663,482 | 613.5 K to 663.5 K (+8.15 %) |
Apr 02 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 1.70 | 50,000 | 85,000 | 50,000 | |
Apr 02 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 23.00 | 50,000 | 1,150,000 | 613,482 | 663.5 K to 613.5 K (-7.54 %) |
Apr 02 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 1.70 | 50,000 | 85,000 | 663,482 | 613.5 K to 663.5 K (+8.15 %) |
Mar 05 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Grant | A | 0.00 | 72,885 | 0 | 613,482 | 540.6 K to 613.5 K (+13.48 %) |
Feb 19 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 1.70 | 50,000 | 85,000 | 100,000 | |
Feb 19 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 1.70 | 50,000 | 85,000 | 150,000 | |
Feb 19 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 22.35 | 50,000 | 1,117,500 | 540,597 | 590.6 K to 540.6 K (-8.47 %) |
Feb 19 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 1.70 | 50,000 | 85,000 | 590,597 | 540.6 K to 590.6 K (+9.25 %) |
Feb 19 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 22.50 | 50,000 | 1,125,000 | 540,597 | 590.6 K to 540.6 K (-8.47 %) |
Feb 19 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 1.70 | 50,000 | 85,000 | 590,597 | 540.6 K to 590.6 K (+9.25 %) |
Feb 17 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 21.91 | 2,858 | 62,619 | 540,597 | 543.5 K to 540.6 K (-0.53 %) |
Feb 05 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 22.56 | 14,982 | 337,994 | 543,455 | 558.4 K to 543.5 K (-2.68 %) |
Feb 05 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Grant | A | 0.00 | 71,293 | 0 | 558,437 | 487.1 K to 558.4 K (+14.63 %) |
Feb 05 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Grant | A | 0.00 | 9,745 | 0 | 487,144 | 477.4 K to 487.1 K (+2.04 %) |
Feb 05 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 22.56 | 14,982 | 337,994 | 543,455 | 558.4 K to 543.5 K (-2.68 %) |
Feb 05 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Grant | A | 0.00 | 71,293 | 0 | 558,437 | 487.1 K to 558.4 K (+14.63 %) |
Feb 05 2021 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Grant | A | 0.00 | 9,745 | 0 | 487,144 | 477.4 K to 487.1 K (+2.04 %) |
Nov 17 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 20.16 | 2,583 | 52,073 | 477,399 | 480 K to 477.4 K (-0.54 %) |
Nov 17 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 20.16 | 9,685 | 195,250 | 479,982 | 489.7 K to 480 K (-1.98 %) |
Nov 17 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 20.16 | 2,685 | 54,130 | 489,667 | 492.4 K to 489.7 K (-0.55 %) |
Sep 04 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 21.58 | 2,517 | 54,317 | 333,191 | 335.7 K to 333.2 K (-0.75 %) |
Sep 04 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Grant | A | 0.00 | 9,745 | 0 | 335,708 | 326 K to 335.7 K (+2.99 %) |
Jun 05 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 1.70 | 100,000 | 170,000 | 200,000 | |
Jun 05 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 22.96 | 100,000 | 2,296,000 | 325,963 | 426 K to 326 K (-23.48 %) |
Jun 05 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 1.70 | 100,000 | 170,000 | 425,963 | 326 K to 426 K (+30.68 %) |
Apr 24 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 1.70 | 100,000 | 170,000 | 300,000 | |
Apr 24 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 26.00 | 100,000 | 2,600,000 | 325,122 | 425.1 K to 325.1 K (-23.52 %) |
Apr 24 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 1.70 | 100,000 | 170,000 | 425,122 | 325.1 K to 425.1 K (+30.76 %) |
Apr 24 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 1.70 | 100,000 | 170,000 | 300,000 | |
Apr 24 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 26.00 | 100,000 | 2,600,000 | 325,122 | 425.1 K to 325.1 K (-23.52 %) |
Apr 24 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 1.70 | 100,000 | 170,000 | 425,122 | 325.1 K to 425.1 K (+30.76 %) |
Mar 06 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 1.70 | 100,000 | 170,000 | 400,000 | |
Mar 06 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 19.60 | 50,000 | 980,000 | 325,122 | 375.1 K to 325.1 K (-13.33 %) |
Mar 06 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 19.20 | 50,000 | 960,000 | 375,122 | 425.1 K to 375.1 K (-11.76 %) |
Mar 06 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 1.70 | 100,000 | 170,000 | 425,122 | 325.1 K to 425.1 K (+30.76 %) |
Feb 21 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.51 | 40,000 | 220,400 | 0 | |
Feb 21 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 21.50 | 40,000 | 860,000 | 325,122 | 365.1 K to 325.1 K (-10.96 %) |
Feb 21 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.51 | 40,000 | 220,400 | 365,122 | 325.1 K to 365.1 K (+12.30 %) |
Feb 18 2020 | GNCA | GENOCEA BIOSCIENCE ... | Schwab Gisela | Director | Option Exercise | A | 2.10 | 9,375 | 19,688 | 9,375 | |
Feb 18 2020 | GNCA | GENOCEA BIOSCIENCE ... | Schwab Gisela | Director | Option Exercise | A | 2.10 | 9,375 | 19,688 | 9,375 | |
Feb 07 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.51 | 50,000 | 275,500 | 40,000 | |
Feb 07 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 18.37 | 50,000 | 918,500 | 325,122 | 375.1 K to 325.1 K (-13.33 %) |
Feb 07 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.51 | 50,000 | 275,500 | 375,122 | 325.1 K to 375.1 K (+15.38 %) |
Jan 09 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.51 | 50,000 | 275,500 | 90,000 | |
Jan 09 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 17.96 | 50,000 | 898,000 | 325,122 | 375.1 K to 325.1 K (-13.33 %) |
Jan 09 2020 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.51 | 50,000 | 275,500 | 375,122 | 325.1 K to 375.1 K (+15.38 %) |
Dec 06 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 17.67 | 4,027 | 71,157 | 325,122 | 329.1 K to 325.1 K (-1.22 %) |
Dec 06 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Grant | A | 0.00 | 15,592 | 0 | 329,149 | 313.6 K to 329.1 K (+4.97 %) |
Dec 05 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.51 | 50,000 | 275,500 | 140,000 | |
Dec 05 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 16.22 | 50,000 | 811,000 | 313,557 | 363.6 K to 313.6 K (-13.75 %) |
Dec 05 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.51 | 50,000 | 275,500 | 363,557 | 313.6 K to 363.6 K (+15.95 %) |
Nov 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 16.51 | 2,583 | 42,645 | 313,557 | 316.1 K to 313.6 K (-0.82 %) |
Nov 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 16.51 | 2,583 | 42,645 | 313,557 | 316.1 K to 313.6 K (-0.82 %) |
Nov 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 16.51 | 9,685 | 159,899 | 316,140 | 325.8 K to 316.1 K (-2.97 %) |
Nov 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 16.51 | 9,685 | 159,899 | 316,140 | 325.8 K to 316.1 K (-2.97 %) |
Nov 06 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.51 | 50,000 | 275,500 | 190,000 | |
Nov 06 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 15.99 | 50,000 | 799,500 | 324,331 | 374.3 K to 324.3 K (-13.36 %) |
Nov 06 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.51 | 50,000 | 275,500 | 374,331 | 324.3 K to 374.3 K (+15.42 %) |
Oct 03 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.51 | 30,000 | 165,300 | 0 | |
Oct 03 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 17.87 | 30,000 | 536,100 | 324,331 | 354.3 K to 324.3 K (-8.47 %) |
Oct 03 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.51 | 30,000 | 165,300 | 354,331 | 324.3 K to 354.3 K (+9.25 %) |
Sep 13 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 19.26 | 2,577 | 49,633 | 324,331 | 326.9 K to 324.3 K (-0.79 %) |
Sep 13 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Grant | A | 0.00 | 10,395 | 0 | 326,908 | 316.5 K to 326.9 K (+3.28 %) |
Apr 03 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 7.18 | 63,109 | 453,123 | 0 | |
Apr 03 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 25.00 | 63,109 | 1,577,725 | 316,513 | 379.6 K to 316.5 K (-16.62 %) |
Apr 03 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 7.18 | 63,109 | 453,123 | 379,622 | 316.5 K to 379.6 K (+19.94 %) |
Mar 27 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 7.18 | 100,000 | 718,000 | 63,109 | |
Mar 27 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 23.14 | 100,000 | 2,314,000 | 316,513 | 416.5 K to 316.5 K (-24.01 %) |
Mar 27 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 7.18 | 100,000 | 718,000 | 416,513 | 316.5 K to 416.5 K (+31.59 %) |
Feb 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.56 | 23,000 | 127,880 | 0 | |
Feb 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.56 | 100,000 | 556,000 | 23,000 | |
Feb 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 22.20 | 23,000 | 510,600 | 316,513 | 339.5 K to 316.5 K (-6.77 %) |
Feb 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.56 | 23,000 | 127,880 | 339,513 | 316.5 K to 339.5 K (+7.27 %) |
Feb 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 21.66 | 100,000 | 2,166,000 | 316,513 | 416.5 K to 316.5 K (-24.01 %) |
Feb 15 2019 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.56 | 100,000 | 556,000 | 416,513 | 316.5 K to 416.5 K (+31.59 %) |
Dec 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.04 | 13,499 | 68,035 | 0 | |
Dec 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.04 | 13,499 | 68,035 | 0 | |
Dec 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 21.02 | 13,499 | 283,749 | 316,513 | 330 K to 316.5 K (-4.09 %) |
Dec 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 21.02 | 13,499 | 283,749 | 316,513 | 330 K to 316.5 K (-4.09 %) |
Dec 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.04 | 13,499 | 68,035 | 330,012 | 316.5 K to 330 K (+4.26 %) |
Dec 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.04 | 13,499 | 68,035 | 330,012 | 316.5 K to 330 K (+4.26 %) |
Nov 16 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 17.45 | 2,479 | 43,259 | 316,513 | 319 K to 316.5 K (-0.78 %) |
Nov 16 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Payment of Exercise | F | 17.45 | 9,296 | 162,215 | 318,992 | 328.3 K to 319 K (-2.83 %) |
Nov 02 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.04 | 12,000 | 60,480 | 13,499 | |
Nov 02 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 14.16 | 12,000 | 169,920 | 328,288 | 340.3 K to 328.3 K (-3.53 %) |
Nov 02 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.04 | 12,000 | 60,480 | 340,288 | 328.3 K to 340.3 K (+3.66 %) |
Oct 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | M | 5.04 | 12,000 | 60,480 | 25,499 | |
Oct 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Sell | S | 17.77 | 12,000 | 213,240 | 328,288 | 340.3 K to 328.3 K (-3.53 %) |
Oct 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Buy | M | 5.04 | 12,000 | 60,480 | 340,288 | 328.3 K to 340.3 K (+3.66 %) |
Sep 12 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres, Prod Dev & Me ... | Option Exercise | A | 18.80 | 129,314 | 2,431,103 | 129,314 | |
Sep 06 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 5.50 | 22,500 | 123,750 | 0 | |
Sep 06 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 18.53 | 22,500 | 416,925 | 328,288 | 350.8 K to 328.3 K (-6.41 %) |
Sep 06 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 5.50 | 22,500 | 123,750 | 350,788 | 328.3 K to 350.8 K (+6.85 %) |
Aug 20 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 5.51 | 50,000 | 275,500 | 30,000 | |
Aug 20 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 5.51 | 50,000 | 275,500 | 328,288 | 278.3 K to 328.3 K (+17.97 %) |
Aug 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 5.50 | 22,500 | 123,750 | 22,500 | |
Aug 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 20.56 | 22,500 | 462,600 | 278,288 | 300.8 K to 278.3 K (-7.48 %) |
Aug 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 5.50 | 22,500 | 123,750 | 300,788 | 278.3 K to 300.8 K (+8.09 %) |
Jul 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 5.50 | 22,500 | 123,750 | 45,000 | |
Jul 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 21.20 | 22,500 | 477,000 | 278,288 | 300.8 K to 278.3 K (-7.48 %) |
Jul 03 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 5.50 | 22,500 | 123,750 | 300,788 | 278.3 K to 300.8 K (+8.09 %) |
Jun 01 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 5.50 | 22,500 | 123,750 | 67,500 | |
Jun 01 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 20.80 | 22,500 | 468,000 | 278,288 | 300.8 K to 278.3 K (-7.48 %) |
Jun 01 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 5.50 | 22,500 | 123,750 | 300,788 | 278.3 K to 300.8 K (+8.09 %) |
May 04 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 5.50 | 22,500 | 123,750 | 90,000 | |
May 04 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 23.47 | 14,700 | 345,009 | 278,288 | 293 K to 278.3 K (-5.02 %) |
May 04 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 22.36 | 7,800 | 174,408 | 292,988 | 300.8 K to 293 K (-2.59 %) |
May 04 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 5.50 | 22,500 | 123,750 | 300,788 | 278.3 K to 300.8 K (+8.09 %) |
Apr 06 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 7.18 | 14,591 | 104,763 | 163,109 | |
Apr 06 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 7.18 | 14,591 | 104,763 | 277,280 | 262.7 K to 277.3 K (+5.55 %) |
Mar 02 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 4.42 | 7,293 | 32,235 | 0 | |
Mar 02 2018 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 4.42 | 7,293 | 32,235 | 262,689 | 255.4 K to 262.7 K (+2.86 %) |
Nov 17 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Payment of Exercise | F | 24.75 | 2,609 | 64,573 | 255,396 | 258 K to 255.4 K (-1.01 %) |
Oct 05 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | A | 24.41 | 150,000 | 3,661,500 | 150,000 | |
Oct 05 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Grant | A | 0.00 | 75,000 | 0 | 258,005 | 183 K to 258 K (+40.98 %) |
Sep 28 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 9.91 | 33,334 | 330,340 | 0 | |
Sep 28 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 9.91 | 33,333 | 330,330 | 33,334 | |
Sep 28 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 9.91 | 33,333 | 330,330 | 66,667 | |
Sep 28 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 23.74 | 33,334 | 791,349 | 183,005 | 216.3 K to 183 K (-15.41 %) |
Sep 28 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 9.91 | 33,334 | 330,340 | 216,339 | 183 K to 216.3 K (+18.21 %) |
Sep 28 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 23.94 | 33,333 | 797,992 | 183,005 | 216.3 K to 183 K (-15.41 %) |
Sep 28 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 9.91 | 33,333 | 330,330 | 216,338 | 183 K to 216.3 K (+18.21 %) |
Sep 28 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 23.68 | 33,333 | 789,325 | 183,005 | 216.3 K to 183 K (-15.41 %) |
Sep 28 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 9.91 | 33,333 | 330,330 | 216,338 | 183 K to 216.3 K (+18.21 %) |
May 16 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 5.04 | 12,501 | 63,005 | 37,499 | |
May 16 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 5.04 | 12,501 | 63,005 | 183,005 | 170.5 K to 183 K (+7.33 %) |
May 03 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 9.91 | 89,910 | 891,008 | 100,000 | |
May 03 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 23.31 | 1,900 | 44,289 | 170,504 | 172.4 K to 170.5 K (-1.10 %) |
May 03 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 23.00 | 88,010 | 2,024,230 | 172,404 | 260.4 K to 172.4 K (-33.80 %) |
May 03 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 9.91 | 89,910 | 891,008 | 260,414 | 170.5 K to 260.4 K (+52.73 %) |
Apr 18 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 9.91 | 10,090 | 99,992 | 189,910 | |
Apr 18 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 9.91 | 10,090 | 99,992 | 168,143 | 158.1 K to 168.1 K (+6.38 %) |
Mar 17 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 7.18 | 32,300 | 231,914 | 177,700 | |
Mar 17 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 4.42 | 17,707 | 78,265 | 7,293 | |
Mar 17 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 22.53 | 50,007 | 1,126,658 | 158,053 | 208.1 K to 158.1 K (-24.03 %) |
Mar 17 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 7.18 | 32,300 | 231,914 | 208,060 | 175.8 K to 208.1 K (+18.38 %) |
Mar 17 2017 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 4.42 | 17,707 | 78,265 | 175,760 | 158.1 K to 175.8 K (+11.20 %) |
Dec 02 2016 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 8.99 | 22,000 | 197,780 | 0 | |
Dec 02 2016 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 16.73 | 22,000 | 368,060 | 158,053 | 180.1 K to 158.1 K (-12.22 %) |
Dec 02 2016 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 8.99 | 22,000 | 197,780 | 180,053 | 158.1 K to 180.1 K (+13.92 %) |
Nov 14 2016 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | M | 8.99 | 22,000 | 197,780 | 22,000 | |
Nov 14 2016 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Sell | S | 15.00 | 22,000 | 330,000 | 158,053 | 180.1 K to 158.1 K (-12.22 %) |
Nov 14 2016 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Buy | M | 8.99 | 22,000 | 197,780 | 180,053 | 158.1 K to 180.1 K (+13.92 %) |
Sep 26 2016 | EXEL | EXELIXIS, INC. | Schwab Gisela | Pres Prod Dev & Med ... | Option Exercise | A | 14.74 | 120,000 | 1,768,800 | 120,000 |